About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

CART-19 Cells for R/R B-cell Lymphoma

NCT03391726·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Jianda Hu, Prof.M.D.Ph.D
CONTACT
86-13959169016 drjiandahu@163.com

Lead

Fujian Medical University

Age

1–65

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Signed written informed consent
Aged between 1-65 years
Patients with relapse/refractory B-cell lymphoma
Cardiac: Left ventricular ejection fraction ≥ 50%
Adequate renal and hepatic function
Performance status: Karnofsky ≥ 70%

You may not be if

Pregnant or lactating females.
Any co-morbidity precluding the administration of CART-19 cells.

The record

StatusUnknown

PhasePhase 2–3

Taking part20

StartedJan 2016

UpdatedJan 5, 2018

Conditions

Relapsed or Refractory B-cell Lymphoma

Where1

Fujian Medical University Union Hospital
Fuzhou, Fujian, China

Clareo Health | CART-19 Cells for R/R B-cell Lymphoma